Involving Antigen-antibody Binding, Specific Binding Protein Assay Or Specific Ligand-receptor Binding Assay Patents (Class 435/7.1)
  • Patent number: 10995072
    Abstract: The present application relates to certain substituted imidazole compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating pain, musculoskeletal inflammation, neuroinflammatory disorders, airway inflammation, itch, dermatitis, colitis and related conditions.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: May 4, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: John Graham Cumming, Frank Xinhe Wu, Karl Henrik Edman, Hongming Chen, Dean Gordon Brown, Roland Werner Burli, Shawn Donald Johnstone, Giles Albert Brown, Benjamin Gerald Tehan, Barry John Teobald, Miles Stuart Congreve
  • Patent number: 10996225
    Abstract: Method, kit and composition for analyzing analytes for modifications using modification site specific antibodies to bind an analyte with his specific modification sites of interest to different dyes simultaneously with an antibody which is specific to the non-modificated analyte binding to another dye to determine the concentration of the analyte for quantification of the modified analyte in the identical sample.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: May 4, 2021
    Inventors: Frank Jeahrling, Friedhelm Bladt, Jessica Witzgall
  • Patent number: 10989717
    Abstract: Diagnosing an oxidative stress (OS) in companion animals comprises screening a bodily fluid sample to detect the presence of an OS biomarker, selectively isoprostane and antioxidants, HODE, microRNAs, TAC, GSH, MDA, and TNF-alpha. The sample can be saliva.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: April 27, 2021
    Assignee: HEMOPET
    Inventors: Winifred Jean Dodds, Denis Marc Callewaert
  • Patent number: 10988804
    Abstract: The invention provides methods, devices, compositions and kits for diagnosing or predicting transplant status or outcome in a subject who has received a transplant.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: April 27, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen R. Quake, Thomas M. Snyder, Hannah Valantine
  • Patent number: 10982155
    Abstract: Asphaltene may be effectively broken into smaller molecules by first elucidating the structure of the asphaltene and then developing a catalyst system based on the elucidated structure. The structure may be determined based on a series of analytical techniques including NMR, FTIR, Raman spectroscopy, XPS, and LDI. The most probable structure is determined using computational methods based on quantum mechanics and classical molecular dynamics and the catalyst system is developed for the most probable structure.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: April 20, 2021
    Inventors: Manjusha Verma, Pradeep Venkataraman, Sivaram Pradhan, Houman Michael Shammai, Wilbur Edward Billups, Scott Wellington
  • Patent number: 10983116
    Abstract: The present invention relates to a system, device, and method for the high throughput multiplexed detection of a wide number of compounds. The invention comprises of a microwell array coupled to a capture agent array to form a plurality of interfaces between a microwell and a set of immobilized capture agents. The set of capture agents comprises a plurality of distinguishable features, with each feature corresponding to the detection of a particular compound of interest. In certain embodiments, each microwell is configured to contain a single cell. The invention is therefore capable of performing a high throughput analysis of single cell profiles, including profiles of secreted compounds.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: April 20, 2021
    Assignee: Yale University
    Inventors: Rong Fan, Yao Lu, Jonathan Chen
  • Patent number: 10981163
    Abstract: This disclosure concerns a method of providing a hydrophobic coating on a microfluidic chip that promotes the discrete flow of at least one liquid. It includes applying the hydrophobic coating onto an area of the microfluidic chip. The disclosure further includes a microfluidic chip that provides discrete flow of at least one liquid.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: April 20, 2021
    Assignee: ABS GLOBAL, INC.
    Inventors: John Larsen, Yu Zhou, Zheng Xia
  • Patent number: 10969389
    Abstract: The present invention provides an in vitro method for monitoring interphase nuclear envelope rupture events in a eukaryotic cell or screening or identifying compound capable of increasing or decreasing the intensity and/or frequency of interphase nuclear envelope rupture events in a eukaryotic cell. These methods relate on a protein having a cytosolic non-nuclear localization in interphase and a non-sequence specific DNA binding activity. Interphase nuclear envelope rupture events are characterized by the presence of the protein of the invention in the nucleus of the eukaryotic cell.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: April 6, 2021
    Inventors: Matthieu Piel, Matteo Gentili, Matthew Raab, Nicolas Manel
  • Patent number: 10967000
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising amino acid sequence of SEQ ID NO:1, a fragment of any one sequence of SEQ ID NO:1, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: April 6, 2021
    Assignee: Gemvax & Kael Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10961284
    Abstract: The present invention discloses a novel recombinant protein antigen and a vaccine composition using the same, in which the novel recombinant protein antigen is derived from the conserved sequence of a TSA56 antigen and can be useful in the diagnosis of infection with tsutsugamushi and as a vaccine for tsutsugamushi.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 30, 2021
    Inventors: Nam Hyuk Cho, Na Young Ha
  • Patent number: 10953104
    Abstract: Disclosed are peptide conjugates comprising an active agent, a spacer moiety, and a dimeric collagen hybridizing peptide comprising a first and second collagen hybridizing peptide, a linker; and a branch point, wherein the first and second collagen hybridizing peptides comprise the sequence of at least (GXY)n, wherein G is glycine, wherein X and Y are any amino acid, and wherein n is any number between 3 and 12. Also disclosed are methods of detecting denatured collagen in a sample comprising contacting a composition comprising any one of the disclosed peptide conjugates to a sample, wherein the active agent comprises a therapeutic agent, and detecting the presence or absence of binding of the peptide conjugate to denatured collagen, the presence of binding indicating the presence of denatured collagen in the sample.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: March 23, 2021
    Inventors: Julian Kessler, Michael S. Yu, Yang Li
  • Patent number: 10946061
    Abstract: The disclosure provides, inter alia, compositions comprising TWIST peptide inhibitors and optionally one or more anti-cancer agents, and methods of using the compositions for the treatment of cancer.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: March 16, 2021
    Assignee: CITY OF HOPE
    Inventor: Carlotta A. Glackin
  • Patent number: 10948387
    Abstract: An improved forced air sampling cassette is provided for the capture, identification, quantification, and analysis of airborne particles such as mold spores, plant pollens, dust, and other airborne pollutants. An adhesive assembly for the cassette is also provided. The cassette makes use of a pressure-sensitive adhesive layer with substantially improved properties for quantitative capture of airborne particles up to about 300 microns in size or larger.
    Type: Grant
    Filed: September 21, 2019
    Date of Patent: March 16, 2021
    Assignee: Perlman Consulting, LLC
    Inventor: Daniel Perlman
  • Patent number: 10947285
    Abstract: The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: March 16, 2021
    Assignee: Amolyt Pharma
    Inventors: David Clemmons, Gang Xi, Thomas Delale, Michel Julien, Thierry Abribat
  • Patent number: 10942190
    Abstract: Provided is a method for measuring amyloid precursor protein (APP) cleavage peptides including amyloid beta (A?) peptides.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: March 9, 2021
    Assignee: Shimadzu Corporation
    Inventor: Naoki Kaneko
  • Patent number: 10940112
    Abstract: This disclosure relates to a targeted PEGylated liposomal gemcitabine (PLG) composition comprising a PEGylated liposome encapsulating one or more agents comprising gemcitabine and a targeting moiety; pharmaceutical composition and methods comprising PLG or producing PLG; and manufacturing equipment for performing the methods.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: March 9, 2021
    Assignee: L.E.A.F. Holdings Group LLC
    Inventors: Clet Niyikiza, Victor Moyo, Zhenghong Xu, Kaniz Khalifa
  • Patent number: 10940248
    Abstract: A method of recovering white blood cells from a leukoreduction filter, the method comprising providing a solution comprising a sugar, flowing a volume of the solution through a leukoreduction filter containing captured white blood cells, and collecting elute from the leukoreduction filter, wherein the elute comprises the solution and recovered white blood cells.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 9, 2021
    Assignee: FENWAL, INC.
    Inventors: Jo Anne B. Alfaro, Yoshikazu Mizobuchi
  • Patent number: 10934549
    Abstract: Disclosed herein are compositions including an aptamer bound to a complex, wherein the complex comprises at least two polypeptides. Accordingly, methods of using the aptamers and making the aptamers are also disclosed.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: March 2, 2021
    Inventors: George Weiner, William Thiel, Paloma Giangrande, Suresh Veeramani, Sue Blackwell
  • Patent number: 10934334
    Abstract: Provided herein are compositions including peptide or nucleic acids encoding peptides and related methods for the treatment of angiogenic conditions such as cancer, vascular disorders such as cardiovascular disorders, and infectious disease.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: March 2, 2021
    Inventor: Mira Sastri
  • Patent number: 10926265
    Abstract: The present invention provides devices, systems, and methods for rapid and easy-to-use in sample thermal cycling or temperature changes for the facilitation of reactions such as but not limited to PCR.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: February 23, 2021
    Assignee: Essenlix Corporation
    Inventors: Stephen Y. Chou, Wei Ding, Yufan Zhang, Hua Tan
  • Patent number: 10927338
    Abstract: The insert shelf (1) is characterized in that it has at least one means (3) with which an incubation medium located in an incubation vessel placed on the insert shelf (1) can be set in motion during an incubation treatment or during an incubation process in an incubator (2). For this purpose, the at least one means (3) can be operated electrically and/or preferably moved mechanically.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: February 23, 2021
    Assignee: IKA-Werke GmbH & Co. KG
    Inventor: Andreas Frei
  • Patent number: 10927400
    Abstract: The invention generally relates to protein standard compositions and methods of making the same. Also contemplated are kits including the protein standard compositions or kits for making the protein standard compositions and methods of using the protein standard compositions to quantify the abundance of a phosphorylated protein in a sample.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: February 23, 2021
    Inventors: Nancy Kendrick, Jon Johansen, Matthew Hoelter, Andrew Koll, Ginny Powers
  • Patent number: 10925921
    Abstract: The invention provides a fermented Pennisetum extract, which has an advantageous effect in treating and preventing a cancer without toxicity to normal cells. The invention also provides a process of preparing the fermented Pennisetum extract and the application of the fermented Pennisetum extract in the treatment or prevention of a cancer.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: February 23, 2021
    Assignee: Sagittarius Life Science Corp.
    Inventor: Ming-Chi Shih
  • Patent number: 10921317
    Abstract: Methods and systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: February 16, 2021
    Assignee: Nautilus Biotechnology, Inc.
    Inventor: Parag Mallick
  • Patent number: 10921331
    Abstract: Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: February 16, 2021
    Assignee: Cleveland Heartlab, Inc.
    Inventors: Cory Bystrom, Timothy Collier
  • Patent number: 10905784
    Abstract: Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: February 2, 2021
    Inventors: Marcus Kelly, Dangshe Ma, William Olson, Richard Tavare, Gavin Thurston
  • Patent number: 10905684
    Abstract: Compounds with amino amide linkers and pharmaceutical compositions and medicaments comprising such compounds are disclosed. In addition, methods of making such compounds and their uses for treating or ameliorating diseases, disorders, or conditions associated with protein malfunction, such as cancer, are provided.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: February 2, 2021
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah Fung, Frank Mercurio, Robert Sullivan
  • Patent number: 10908141
    Abstract: The invention provides methods and kits for detecting the presence of, the amount of, or the concentration of a substantially non-emitting metal in a sample by a) providing a sensitizer to a chelator of the substantially non-emitting metal thereby creating a sensitized-metal complex; b) adding an unsensitized chelate, and c) detecting a signal from the unsensitized chelate. The substantially non-emitting metal may be gadoliniumn and may exist in complex with a chelator. The unsensitized chelate may be terbium (Tb) or europium (Eu) and the detecting a signal may be performed by fluorescence.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: February 2, 2021
    Assignee: New York University
    Inventors: Stewart Russell, Edward A. Fisher, Youssef Zaim Wadghiri, Ryan Casey
  • Patent number: 10900872
    Abstract: Apparatuses and methods for removing magnetic particles from suspensions are described. One embodiment of the apparatus is called a magnetic needle.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: January 26, 2021
    Assignee: Imagion Biosystems Inc.
    Inventors: Edward R Flynn, Erika Vreeland
  • Patent number: 10900091
    Abstract: The present invention provides methods for assessing the likelihood of effectiveness of chemotherapy such as oxaliplatin treatment in colorectal cancer patients as well as their survival prospect by determining the level of miR-133a in the cancer tissue. A kit useful for such methods are also provided.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: January 26, 2021
    Assignee: The Chinese University of Hong Kong
    Inventors: Siu Man Simon Ng, Jun Yu, Joseph Jao Yiu Sung, Yujuan Dong
  • Patent number: 10900955
    Abstract: The present invention pertains to a polyclonal or monoclonal antibody specifically binding to BoNT/E-cleaved SNAP-25.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 26, 2021
    Inventors: Cornelia Bruenn, Gerd Mander
  • Patent number: 10882919
    Abstract: The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: January 5, 2021
    Assignee: Rallybio IPA, LLC
    Inventors: Terje Michaelsen, Oistein Ihle, Tor Brynjar Stuge, Anne Husebekk, Heidi Tiller, Mariana Eksteen, Bjorn Ragnar Skogen
  • Patent number: 10883000
    Abstract: Materials and methods of modifying an electrode surface are described herein. Self-assembled monolayers (SAM) of polyaromatic molecules covalently attached and form a graphitic-like surface on the electrode surface. After covalent attachment of the polyaromatic monolayer to the surface, polyaromatic-functionalized molecular species is physisorbed onto the surface using the ?-interactions. This concept can be applied to generate high performance electrode materials modified with molecular species. The electrode materials can be applied in photoelectrochemical cells, electrochemical cells, sensors, and electrochromic materials. This approach overcomes the major synthetic challenges to modifying surfaces with molecular species, in addition to protecting the surfaces from corrosion.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 5, 2021
    Inventors: Jenny Y. Yang, Brian R. Lydon
  • Patent number: 10879416
    Abstract: A cytometer includes an avalanche photodiode, a switching power supply, a filter, and voltage adjustment circuitry. The switching power supply includes a feedback loop. The filter is electrically connected between the switching power supply and the avalanche photodiode. The voltage adjustment circuitry adjusts a voltage on the feedback loop based at least in part on a voltage measured between the filter and the avalanche photodiode.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: December 29, 2020
    Assignee: ABS Global, Inc.
    Inventors: Frederick Savage, Glenn J. Szejna, Zheng Xia
  • Patent number: 10874677
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: December 29, 2020
    Assignees: Hoffmann-La Roche Inc., CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Xiaoping Zhang, Kimio Terao
  • Patent number: 10877044
    Abstract: The invention provides methods for characterizing a target protein wherein a mass spectrum of digest peptides of the target protein is acquired and compared with measured reference mass spectra of digest peptides of reference proteins or of proteins of reference host cells. The comparison comprises determining similarity scores of the intensity patterns of the mass spectrum and the reference mass spectra. The characterization comprises assigning the target protein to a reference protein having a reference mass spectrum with a similarity score above a predetermined threshold.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: December 29, 2020
    Inventors: Detlev Suckau, Anja Resemann, Waltraud Evers
  • Patent number: 10871459
    Abstract: Computing systems and methods for characterizing a protein are provided. Each residue in a subset of the protein is in an amino acid type set and is represented by a vertex in a graph G formed from an atomic model of the protein. NMR data, acquired with some of the residues of the protein isotopically labeled, is used to form a graph H with each vertex representing a different residue of the protein and assigned one or more amino types. Placements of H onto G are formed, each including mappings assigning vertices in H to vertices in G subject to the constraints that vertices in H mapped to vertices in G cannot be of different amino acid types and edges between pairs of vertices in H must map to corresponding edges in G. For each vertex in H, the number of different valid mappings to G is determined by polling the placements as a constraint satisfaction problem and is deemed assigned when only a single unique assignment is identified.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: December 22, 2020
    Assignee: The Regents of the University of California
    Inventors: Demetrios Achlioptas, Nikolaos G. Sgourakis
  • Patent number: 10871436
    Abstract: The invention relates to a new type of element encoded particles suitable for the attachment of bio molecules to enable massively multiplex bio-analytical methods, and to calibrate and tune the elemental flow cytometer mass spectrometer (FC-MS).
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: December 22, 2020
    Assignee: Fluidigm Canada Inc.
    Inventors: Mitchell A. Winnik, Cedric Van-Caeyzeele, Vladimir I. Baranov
  • Patent number: 10865412
    Abstract: Insulin-like growth factor-binding protein 7 (IGFBP7) has been identified herein as a therapeutic target for the treatment or prevention of heart diseases, metabolic diseases, and other related disease or conditions. IGFBP7 inhibitors having IGFBP7 expression and/or activity reducing properties are described herein. Treatment methods, and uses, relating to such IGFBP7 inhibitors for the treatment or prevention of heart failure, IGFBP7-related metabolic diseases, and related diseases or conditions are provided.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: December 15, 2020
    Assignee: Ottawa Heart Institute Research
    Inventors: Peter Liu, Liyong Zhang
  • Patent number: 10867702
    Abstract: For patients who exhibit or may exhibit primary or comorbid disease, pharmacological phenotypes may be predicted through the collection of panomic data over a period of time. A machine learning engine may generate a statistical model based on training data from training patients to predict pharmacological phenotypes, including drug response and dosing, drug adverse events, disease and comorbid disease risk, drug-gene, drug-drug, and polypharmacy interactions. Then the model may be applied to data for new patients to predict their pharmacological phenotypes, and enable decision making in clinical and research contexts, including drug selection and dosage, changes in drug regimens, polypharmacy optimization, monitoring, etc., to benefit from additional predictive power, resulting in adverse event and substance abuse avoidance, improved drug response, better patient outcomes, lower treatment costs, public health benefits, and increases in the effectiveness of research in pharmacology and other biomedical fields.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: December 15, 2020
    Inventors: Brian D. Athey, Ari Allyn-Feuer, Gerald A. Higgins, James S. Burns, Alexandr Kalinin, Brian Pauls, Alex Ade, Narathip Reamaroon
  • Patent number: 10865244
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: December 15, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • Patent number: 10858671
    Abstract: The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: December 8, 2020
    Assignees: University of Copenhagen, Dansmarks Tekniske Universitet
    Inventors: Henrik Clausen, Zhang Yang, Adnan Fevzi Halim, Eric Bennett, Carsten Behrens, Malene Bech Vester-Christensen, Shamim Herbert Rahman
  • Patent number: 10859583
    Abstract: A feces sampling container having an increased storage stability of a component in a feces sample such as hemoglobin to enable the measurement of a component in a feces sample with a small amount of feces collected. The container includes a container body, and a feces sampling stick having a gripping part on one side and a stick part on the other side, the stick part having a feces sampling part in the vicinity of the tip, wherein the container body comprises an opening part through which the feces sampling part of the feces sampling stick is inserted, and a feces container chamber in which a desiccant is enclosed, wherein the feces sample held by the feces sampling part is dried by a contact of the feces sampling part, which is inserted through the opening part and holding the feces sample, with the desiccant.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: December 8, 2020
    Inventors: Yasumasa Shimada, Kohei Tsuchiya, Yuki Kaname
  • Patent number: 10857243
    Abstract: The invention relates to an enzymatically responsive product that includes an amino acid residue conjugated to a magnetic particle, wherein the amino acid residue is phosphorylated or sulfated or comprises an ester-moiety linked via peptide bond. Compositions containing the enzymatically responsive product, and the use thereof for separating distinct types of mammalian cells (e.g., cancer cells from normal cells), for treating a cancerous condition, and imaging cancer cells are also disclosed.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: December 8, 2020
    Inventors: Xuewen Du, Jie Zhou, Bing Xu
  • Patent number: 10859585
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 8, 2020
    Assignee: The Scripps Research Institute
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta, Jonathan Hulce
  • Patent number: 10859574
    Abstract: Antibiotics (Abx) are the world's most misused drugs. Antibiotics misuse occurs when the drug is administered in case of a non-bacterial infection (such as a viral infection) for which it is ineffective. Overall, it is estimated that 40-70% of the worldwide Abx courses are mis-prescribed. The financial and health consequences of Abx over-prescription include the direct cost of the drugs, as well as the indirect costs of their side effects, which are estimated at >$15 billion annually. Furthermore, over-prescription directly causes the emergence of Abx-resistant strains of bacteria, which are recognized as one of the major threats to public health today. This generates an immediate need for reliable diagnostics to assist physicians in correct Abx prescription, especially at the point-of-care (POC) where most Abx are prescribed. Accordingly, some aspects of the present invention provide methods using biomarkers for rapidly detecting the source of infection and administrating the appropriate treatment.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: December 8, 2020
    Assignee: MeMed Diagnostics Ltd.
    Inventors: Kfir Oved, Eran Eden
  • Patent number: 10854338
    Abstract: Biomarker signatures for predicting breast cancer tumor aggressiveness. The signatures are derived from QTA-based parameters from a first population of low risk scores and a second population of high risk scores. The signatures may be expressed in the form log (RS)=Mx+B for linear modeling, or for logistic modeling the signatures may be expressed as either p=ex/[1+ex] where x=Ay+B, or in the form log it(p)=C(PR)+Ay+B, where y is a QTA based parameter.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 1, 2020
    Inventor: Ronald L. Korn
  • Patent number: 10845278
    Abstract: An apparatus for pretreatment of a desired sample in a discrete fluid analyzing instrument includes a frame rotatably mounted on or within the discrete fluid analyzing instrument with a column for immobilizing at least one substance or analyte from the sample. The substance or analyte is reversibly immobilized. A first fluid transport line is provided for aspirating the sample into the column and for ejecting the substance or analyte eluted from the column. A pump is provided for pumping the sample through the column with a second fluid transport line connecting the pump to the column. A member is providing to supply the eluted substance or analyte to the discrete fluid analyzing instrument for measurement of at least one property of the substance or analyte. A device is provided for simultaneously or consecutively directing any non-pretreated sample or any subsample directly to the discrete fluid analyzing instrument.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: November 24, 2020
    Assignee: Thermo Fisher Scientific Oy
    Inventors: Sari Tikanoja, Annu Suoniemi, Johan Finell
  • Patent number: 10844106
    Abstract: The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform for increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 24, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Douglas S. Jones, Mihalis S. Kariolis, Ping-Chuan Tsai
  • Patent number: 10837961
    Abstract: Macromolecular imprinted silica particles (“MIP”) in the presence of polymer grafted carbon black are disclosed. The disclosed molecular imprinted beads can detect disease in body fluids. For the silica gel matrix, tetraethyl orthosilicate (TEOS) was used as the backbone monomer and 3-aminopropy/triethoxysilane (APS) as a functional monomer. Carbon black was added to the sol-gel process, yielding black silica particles. Furthermore, sodium dodecyl sulfate (SDS) was used as a structure-directing agent to increase network diffusion of the template. A total of 16 MIPs were synthetized in parallel with variables that evaluate the role of key reactants in the synthesis procedure. Agglomeration tests were performed with all 16 MIPs in the presence of their template, alongside their respective controls using only phosphate buffered saline (“PBS”). Each of the MIPs was evaluated using a novel device capable of simultaneously measuring up to four samples for near infrared transmission.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: November 17, 2020
    Inventor: Thomas Boland